Skip to Content
NEW
A vastly improved search engine helps you find the latest on companies, business leaders, and news more easily.
SIGN IN

In the fall of 2019, Vertex launched Trikafta, the latest of its breakthrough therapies for people with cystic fibrosis. Capable of treating up to 90% of those who suffer from the progressive, life-threatening disease, the drug has already been used to treat thousands of patients in the U.S. and recently won approval in the EU. The company’s sales—$4.2 billion in 2019—have averaged 35% annual growth over the past three years. One setback: The biotech’s stock fell 23% in October after it scrapped a new drug in Phase II clinical trials.

Courtesy of Vertex
Lists ranking Vertex Pharmaceuticals
RANK16
Future 50 - 2020Explore this year's ranking of the 50 companies wi...READ MOREview in list
RANK6
100 Fastest-Growing Companies - 2020Collectively, the ranked companies produced a thre...READ MOREview in list
RANK626
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MOREview in list